WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides
Open Access
- 12 September 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8141
Abstract
Extensive clinical studies have convincingly demonstrated that fungal infections constitute a mounting global health concern. Candida albicans, C. auris, Aspergillus fumigatus, and Cryptococcus neoformans were classified by the WHO as critical priority fungi due to their widespread prevalence, high mortality rates associated with invasive mycoses, and the increasing spread of resistant strains. The currently available antifungal arsenal, comprising four major classes (azoles, polyenes, echinocandins, and flucytosine), is critically insufficient. Resistance to these agents is escalating worldwide, while the approval of new drugs remains alarmingly slow. This review provides a comprehensive overview of the molecular mechanisms underlying resistance to conventional and emerging antimycotics in critical priority fungi, including recently approved and investigational agents such as oteseconazole, rezafungin, ibrexafungerp, fosmanogepix, and olorofim. It examines current strategies to overcome resistance, including combination therapy, drug repurposing, targeted delivery, antibiofilm approaches, immunotherapy, and the application of natural antifungal compounds. Special emphasis is placed on antifungal peptides (AFPs) derived from plants, animals, bacteria, and fungi, along with their synthetic analogs, all of which have demonstrated efficacy against critical priority fungi. The review primarily focuses on the molecular targets of AFPs and on the development of fungal resistance under prolonged exposure, compared with conventional antifungals, in order to evaluate their potential as prototypes for next-generation antimycotics.Keywords
Funding Information
- Russian Science Foundation (26-15-00431)
This publication has 294 references indexed in Scilit:
- Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agentPharmacology Research & Perspectives, 2020
- Vicilin‐like peptides from Capsicum baccatum L. seeds are α‐amylase inhibitors and exhibit antifungal activity against important yeasts in medical mycologyPeptide Science, 2014
- The IL‐36 receptor pathway regulates Aspergillus fumigatus‐induced Th1 and Th17 responsesEuropean Journal of Immunology, 2012
- The small molecular mass antifungal protein of Penicillium chrysogenum – a mechanism of action oriented reviewJournal of Basic Microbiology, 2011
- Linear Analogues of Human β‐Defensin 3: Concepts for Design of Antimicrobial Peptides with Reduced Cytotoxicity to Mammalian CellsChemBioChem, 2008
- The Penicillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studiesCellular and Molecular Life Sciences, 2007
- Structure–activity relationship studies of gomesin: Importance of the disulfide bridges for conformation, bioactivities, and serum stabilityPeptide Science, 2005
- RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUSCytokine, 2001
- Solution structure, backbone dynamics and chitin binding of the anti-fungal protein from Streptomyces tendae TÜ901 1 1Edited by M. F. SummersJournal of Molecular Biology, 2001
- Antifungal Spectrum and Fungicidal Mechanism of an N-Terminal Peptide of Bovine LactoferrinJournal of Infection and Chemotherapy, 1996